ArticleLipids in health and disease2026
Remnant cholesterol and lipid ratios predict the relapse of neuromyelitis optica spectrum disorder.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNeuromyelitis optica spectrum disorder (NMOSD) is a demyelinating condition in the central nervous system whose relapses cause severe disability progression. Although conventional blood lipid markers are linked to disease course and outcomes, the predictive value of emerging lipid indicators, such as remnant cholesterol (RC) and lipid ratios, for NMOSD relapse remains unclear.
methodsThe single-centre retrospective study enrolled a total of 245 patients diagnosed with NMOSD, based on the availability of clinical and laboratory data. To evaluate RC and lipid ratios in predicting NMOSD relapse, multivariate Cox proportional hazards models and restricted cubic spline evaluations were applied. Predictive performance was assessed using the concordance index (C-index), continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Subgroup evaluations examined the stability of the observed RC-relapse connection across diverse patient strata. Cumulative hazard function curves illustrated the clinical relevance of the RC inflection point. Additionally, mediation analyses tested whether inflammatory markers mediated the RC effect on relapse.
resultsAmong 245 NMOSD patients, 55.10% of the patients relapsed during follow-up. RC, non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, total cholesterol and low-density lipoprotein cholesterol levels emerged as independent determinants of relapse across both continuous and categorical Cox models, after adjusting for demographic, clinical and therapy-associated factors. An "S"-shaped nonlinear relationship was observed between RC values and relapse risk, with a turning point at 0.46 mmol/L: protective below, risk factor above. Performance metrics (C-index, NRI, IDI) indicated that RC significantly improved relapse prediction. The RC-relapse association persisted across subgroups, with the inflection point effectively distinguishing relapsing patients in the anti-aquaporin 4-immunoglobulin G seropositive and monoclonal antibody treatment group. Mediation analysis revealed increased neutrophil ratio and decreased lymphocyte ratio partially mediated RC's effect on relapse.
conclusionsRC was identified as the most robust lipid metabolism indicator for predicting NMOSD relapse, displaying an inflection at 0.46 mmol/L. Neutrophil ratio and lymphocyte ratio may partially mediate the relationship between elevated RC and relapse. These findings aid timely recognition of patients at elevated risk and provision of individualised therapeutic interventions to reduce disability and improve long-term outcomes in this debilitating disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.